RxDoctor Payments Data

April Brumley

Nurse Practitioner · Saint Louis, MONPI 1982707147

Payments from drug & device makers

$335in general payments, 2019–2025

Across 17 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$65
  • Daiichi Sankyo Inc.$57
  • Amarin Pharma, Inc.$36
  • Lilly USA, LLC$34
  • Boehringer Ingelheim$34
  • AstraZeneca$29
  • plus $80 from 4 others

What the payments were for

  • Food & beverage$335100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$335 in reported general payments places this provider in the 60th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$36,518
Medicare patients
104
Services billed
426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$45,288
OzempicSemaglutide28$36,402
JanuviaSitagliptin Phosphate23$34,224
JardianceEmpagliflozin19$30,747
MounjaroTirzepatide24$26,393
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$20,226
XareltoRivaroxaban29$17,414
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$14,598
Semglee (Yfgn) PenInsulin Glargine-Yfgn21$14,126
MyrbetriqMirabegron15$13,598
Combivent RespimatIpratropium/Albuterol Sulfate11$9,119
FarxigaDapagliflozin Propanediol13$8,402
SymbicortBudesonide/Formoterol Fumarate14$4,381
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate23$3,641
Atorvastatin Calcium450$2,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$34$39,86630 claims
Novo NordiskOzempic$14$36,40228 claims
MerckJanuvia$25$34,22423 claims
Lilly USA, LLCMounjaro$34$26,39324 claims
AstraZenecaFarxiga, Symbicort$29$12,78327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →